3/27
08:42 am
nuvb
Nuvation Bio (NUVB) had its "outperform" rating reaffirmed by Wedbush. They now have a $11.00 price target on the stock.
Medium
Report
Nuvation Bio (NUVB) had its "outperform" rating reaffirmed by Wedbush. They now have a $11.00 price target on the stock.
3/27
03:18 am
nuvb
Nuvation Bio Inc. (NUVB): Billionaire David Abrams Has a Long-Term Bet on This Stock [Yahoo! Finance]
Medium
Report
Nuvation Bio Inc. (NUVB): Billionaire David Abrams Has a Long-Term Bet on This Stock [Yahoo! Finance]
3/26
04:43 pm
nuvb
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency [Yahoo! Finance]
Medium
Report
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency [Yahoo! Finance]
3/26
04:05 pm
nuvb
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
Medium
Report
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
3/26
10:00 am
nuvb
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB
3/24
05:13 pm
nuvb
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB
3/21
05:15 pm
nuvb
NUVB Investors Have Opportunity to Join Nuvation Bio Inc. Fraud Investigation with the Schall Law Firm
Low
Report
NUVB Investors Have Opportunity to Join Nuvation Bio Inc. Fraud Investigation with the Schall Law Firm
3/21
11:16 am
nuvb
Is It Time To Reassess Nuvation Bio (NUVB) After Its Recent Share Price Swings [Yahoo! Finance]
Low
Report
Is It Time To Reassess Nuvation Bio (NUVB) After Its Recent Share Price Swings [Yahoo! Finance]
3/19
10:00 am
nuvb
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB
3/17
05:33 pm
nuvb
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB
3/17
04:55 pm
nuvb
Nuvation Bio to Present Pivotal IBTROZI® (Taletrectinib) Data in TKI-Naïve and TKI-Pretreated Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer at AACR 2026 [Yahoo! Finance]
Low
Report
Nuvation Bio to Present Pivotal IBTROZI® (Taletrectinib) Data in TKI-Naïve and TKI-Pretreated Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer at AACR 2026 [Yahoo! Finance]
3/17
04:35 pm
nuvb
Nuvation Bio to Present Pivotal IBTROZI® (Taletrectinib) Data in TKI-Naïve and TKI-Pretreated Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer at AACR 2026
Low
Report
Nuvation Bio to Present Pivotal IBTROZI® (Taletrectinib) Data in TKI-Naïve and TKI-Pretreated Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer at AACR 2026
3/13
03:27 pm
nuvb
RBC Capital Lifts PT on Nuvation Bio (NUVB) to $13 From $12 – Here's Why [Yahoo! Finance]
Low
Report
RBC Capital Lifts PT on Nuvation Bio (NUVB) to $13 From $12 – Here's Why [Yahoo! Finance]
3/13
09:12 am
nuvb
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm
Neutral
Report
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm
3/12
10:00 am
nuvb
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB
3/10
04:03 pm
nuvb
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB
3/6
02:21 pm
nuvb
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm
Low
Report
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm
3/4
11:48 am
nuvb
Nuvation Bio (NUVB) Generates $62.9M Annual Revenue Following Successful Erozi Launch [Yahoo! Finance]
Medium
Report
Nuvation Bio (NUVB) Generates $62.9M Annual Revenue Following Successful Erozi Launch [Yahoo! Finance]
3/4
08:30 am
nuvb
Nuvation Bio Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Medium
Report
Nuvation Bio Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
3/4
07:35 am
nuvb
Nuvation Bio Transitions To Commercial Stage With Iptrozi And Safusidenib Progress [Yahoo! Finance]
Medium
Report
Nuvation Bio Transitions To Commercial Stage With Iptrozi And Safusidenib Progress [Yahoo! Finance]
3/3
04:09 pm
nuvb
Nuvation Bio Stock Up 130% This Past Year as One Fund Discloses $3 Million Buy [Yahoo! Finance]
Medium
Report
Nuvation Bio Stock Up 130% This Past Year as One Fund Discloses $3 Million Buy [Yahoo! Finance]
3/3
02:22 pm
nuvb
Nuvation Bio (NUVB) had its price target lowered by UBS Group AG from $10.00 to $7.00. They now have a "neutral" rating on the stock.
Low
Report
Nuvation Bio (NUVB) had its price target lowered by UBS Group AG from $10.00 to $7.00. They now have a "neutral" rating on the stock.
3/3
10:46 am
nuvb
Nuvation Bio (NUVB) had its price target raised by Royal Bank Of Canada from $12.00 to $13.00. They now have an "outperform" rating on the stock.
Medium
Report
Nuvation Bio (NUVB) had its price target raised by Royal Bank Of Canada from $12.00 to $13.00. They now have an "outperform" rating on the stock.
3/3
02:42 am
nuvb
Nuvation Bio outlines first-line IBTROZI growth strategy with 50-month median DOR amid expanding global partnerships [Seeking Alpha]
High
Report
Nuvation Bio outlines first-line IBTROZI growth strategy with 50-month median DOR amid expanding global partnerships [Seeking Alpha]
3/3
02:42 am
nuvb
Nuvation Bio Inc. (NUVB) Q4 2025 Earnings Call Transcript [Seeking Alpha]
High
Report
Nuvation Bio Inc. (NUVB) Q4 2025 Earnings Call Transcript [Seeking Alpha]